Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Primary cervical screening with high risk human papillomavirus testing: observational study.

Rebolj M, Rimmer J, Denton K, Tidy J, Mathews C, Ellis K, Smith J, Evans C, Giles T, Frew V, Tyler X, Sargent A, Parker J, Holbrook M, Hunt K, Tidbury P, Levine T, Smith D, Patnick J, Stubbs R, Moss S, Kitchener H.

BMJ. 2019 Feb 6;364:l240. doi: 10.1136/bmj.l240.

2.

Reply to 'Comment on 'Addition of ultrasound to mammography in the case of dense breast tissue: systematic review and meta-analysis".

Rebolj M, Brentnall A, Duffy SW.

Br J Cancer. 2018 Nov;119(11):1444. doi: 10.1038/s41416-018-0247-y. Epub 2018 Nov 9. No abstract available.

PMID:
30410058
3.

Is a delay in the introduction of human papillomavirus-based cervical screening affordable?

Castañon A, Rebolj M, Sasieni P.

J Med Screen. 2019 Mar;26(1):44-49. doi: 10.1177/0969141318800355. Epub 2018 Oct 3.

PMID:
30280637
4.

Addition of ultrasound to mammography in the case of dense breast tissue: systematic review and meta-analysis.

Rebolj M, Assi V, Brentnall A, Parmar D, Duffy SW.

Br J Cancer. 2018 Jun;118(12):1559-1570. doi: 10.1038/s41416-018-0080-3. Epub 2018 May 8.

PMID:
29736009
5.

As you like it: How the same data can support manifold views of overdiagnosis in breast cancer screening.

Njor SH, Paci E, Rebolj M.

Int J Cancer. 2018 Sep 15;143(6):1287-1294. doi: 10.1002/ijc.31420. Epub 2018 Apr 25.

PMID:
29633249
6.

Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study.

Rozemeijer K, Naber SK, Penning C, Overbeek LI, Looman CW, de Kok IM, Matthijsse SM, Rebolj M, van Kemenade FJ, van Ballegooijen M.

BMJ. 2017 Feb 14;356:j504. doi: 10.1136/bmj.j504.

7.

Human papillomavirus self-sampling for screening nonattenders: Opt-in pilot implementation with electronic communication platforms.

Lam JU, Rebolj M, Møller Ejegod D, Pedersen H, Rygaard C, Lynge E, Thirstrup Thomsen L, Krüger Kjaer S, Bonde J.

Int J Cancer. 2017 May 15;140(10):2212-2219. doi: 10.1002/ijc.30647. Epub 2017 Feb 27.

8.

Assessing opportunities for coordinated R&D in early cancer detection and management in Europe.

Ussi AE, Rebolj M, Thorat MA, Bietrix F, Fauvel AC, Hajdúch M, Hill C, Walker I, van Engeland M, Cuzick J, Meijer G.

Int J Cancer. 2017 Apr 1;140(7):1700-1701. doi: 10.1002/ijc.30564. Epub 2016 Dec 27. No abstract available.

9.

Differential Detection of Human Papillomavirus Genotypes and Cervical Intraepithelial Neoplasia by Four Commercial Assays.

Rebolj M, Bonde J, Preisler S, Ejegod D, Rygaard C, Lynge E.

J Clin Microbiol. 2016 Nov;54(11):2669-2675. Epub 2016 Aug 17.

10.

Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study.

Preisler S, Rebolj M, Ejegod DM, Lynge E, Rygaard C, Bonde J.

BMC Cancer. 2016 Jul 20;16:510. doi: 10.1186/s12885-016-2518-4.

11.

Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above.

Rebolj M, Bonde J, Preisler S, Ejegod D, Rygaard C, Lynge E.

PLoS One. 2016 Jan 20;11(1):e0147326. doi: 10.1371/journal.pone.0147326. eCollection 2016.

12.

Cervical histology after routine ThinPrep or SurePath liquid-based cytology and computer-assisted reading in Denmark.

Rebolj M, Rask J, van Ballegooijen M, Kirschner B, Rozemeijer K, Bonde J, Rygaard C, Lynge E.

Br J Cancer. 2015 Nov 3;113(9):1259-74. doi: 10.1038/bjc.2015.339. Epub 2015 Oct 8.

13.

A daunting challenge: Human Papillomavirus assays and cytology in primary cervical screening of women below age 30years.

Rebolj M, Bonde J, Ejegod D, Preisler S, Rygaard C, Lynge E.

Eur J Cancer. 2015 Jul;51(11):1456-66. doi: 10.1016/j.ejca.2015.04.012. Epub 2015 May 12.

14.
15.

Hysterectomy and its impact on the calculated incidence of cervical cancer and screening coverage in Denmark.

Lam JU, Lynge E, Njor SH, Rebolj M.

Acta Oncol. 2015;54(8):1136-43. doi: 10.3109/0284186X.2015.1016625. Epub 2015 Mar 24.

PMID:
25800858
16.

Mothers' and their daughters' use of preventive measures against cervical cancer.

Sander BB, Vázquez-Prada M, Rebolj M, Valentiner-Branth P, Lynge E.

Scand J Public Health. 2015 Jun;43(4):415-22. doi: 10.1177/1403494815574155. Epub 2015 Mar 5.

PMID:
25743877
17.

Psychological effects of diagnosis and treatment of cervical intraepithelial neoplasia: a systematic review.

Frederiksen ME, Njor S, Lynge E, Rebolj M.

Sex Transm Infect. 2015 Jun;91(4):248-56. doi: 10.1136/sextrans-2014-051754. Epub 2014 Dec 15. Review.

PMID:
25512668
18.

Cervical cancer screening in the Faroe Islands.

Hammer T, Lynge E, Djurhuus GW, Joensen JE, Køtlum JE, Hansen SÓ, Sander BB, Mogensen O, Rebolj M.

Acta Oncol. 2015 Feb;54(2):210-6. doi: 10.3109/0284186X.2014.986287. Epub 2014 Dec 15.

PMID:
25495570
19.

Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytology.

Rebolj M, Lynge E, Ejegod D, Preisler S, Rygaard C, Bonde J.

Gynecol Oncol. 2014 Dec;135(3):474-80. doi: 10.1016/j.ygyno.2014.10.014. Epub 2014 Oct 23.

20.

Risk of cervical cancer in women with autoimmune diseases, in relation with their use of immunosuppressants and screening: population-based cohort study.

Dugué PA, Rebolj M, Hallas J, Garred P, Lynge E.

Int J Cancer. 2015 Mar 15;136(6):E711-9. doi: 10.1002/ijc.29209. Epub 2014 Sep 24.

21.

Increased risk of high-grade squamous intraepithelial lesions in systemic lupus erythematosus: additional data from Denmark.

Dugué PA, Lynge E, Rebolj M.

Autoimmun Rev. 2014 Dec;13(12):1241-2. doi: 10.1016/j.autrev.2014.08.004. Epub 2014 Aug 20. No abstract available.

PMID:
25151614
22.

HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 human papillomavirus genotype microarray system.

Bonde J, Rebolj M, Ejegod DM, Preisler S, Lynge E, Rygaard C.

BMC Infect Dis. 2014 Jul 26;14:413. doi: 10.1186/1471-2334-14-413.

23.

Cervical cancer screening at crossroads.

Lynge E, Rygaard C, Baillet MV, Dugué PA, Sander BB, Bonde J, Rebolj M.

APMIS. 2014 Aug;122(8):667-73. doi: 10.1111/apm.12279. Review.

PMID:
25046198
24.

Trends of cervical cancer in Greenland: a 60-year overview.

Sander BB, Rebolj M, Lynge E.

Acta Oncol. 2014 Apr;53(4):452-61. doi: 10.3109/0284186X.2014.883462. Epub 2014 Feb 11. Review.

PMID:
24512341
25.

Condom use in prevention of Human Papillomavirus infections and cervical neoplasia: systematic review of longitudinal studies.

Lam JU, Rebolj M, Dugué PA, Bonde J, von Euler-Chelpin M, Lynge E.

J Med Screen. 2014 Mar;21(1):38-50. doi: 10.1177/0969141314522454. Epub 2014 Jan 31. Review.

PMID:
24488594
26.

Disagreement between human papillomavirus assays: an unexpected challenge for the choice of an assay in primary cervical screening.

Rebolj M, Preisler S, Ejegod DM, Rygaard C, Lynge E, Bonde J.

PLoS One. 2014 Jan 20;9(1):e86835. doi: 10.1371/journal.pone.0086835. eCollection 2014.

27.

Mortality of non-participants in cervical screening: Register-based cohort study.

Dugué PA, Lynge E, Rebolj M.

Int J Cancer. 2014 Jun 1;134(11):2674-82. doi: 10.1002/ijc.28586. Epub 2013 Nov 29.

28.

Incidence of genital warts in young Danish women.

Lynge E, Kragstrup J, Bjerrum L, Rebolj M.

Clin Infect Dis. 2014 Feb;58(4):601-2. doi: 10.1093/cid/cit754. Epub 2013 Nov 18. No abstract available.

PMID:
24253245
29.

Lead time and down-staging in the survival of cervical cancer cases detected by screening.

Dugué PA, Rebolj M, Lynge E.

Prev Med. 2013 Oct;57(4):403. doi: 10.1016/j.ypmed.2013.07.025. Epub 2013 Aug 14. No abstract available.

PMID:
23954186
30.

Prevalence of Human Papillomavirus infection in unselected SurePath samples using the APTIMA HPV mRNA assay.

Rebolj M, Preisler S, Ejegod DM, Bonde J, Rygaard C, Lynge E.

J Mol Diagn. 2013 Sep;15(5):670-7. doi: 10.1016/j.jmoldx.2013.04.002. Epub 2013 Jul 1.

PMID:
23827659
31.

Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay.

Preisler S, Rebolj M, Untermann A, Ejegod DM, Lynge E, Rygaard C, Bonde J.

PLoS One. 2013;8(3):e59765. doi: 10.1371/journal.pone.0059765. Epub 2013 Mar 22.

32.

Long-term adherence to follow-up after treatment of cervical intraepithelial neoplasia: nationwide population-based study.

Barken SS, Lynge E, Andersen ES, Rebolj M.

Acta Obstet Gynecol Scand. 2013 Jul;92(7):852-7. doi: 10.1111/aogs.12116. Epub 2013 Mar 12.

PMID:
23418941
33.

Patterns of cervical coinfection with multiple human papilloma virus types in a screening population in Denmark.

Goldman B, Rebolj M, Rygaard C, Preisler S, Ejegod DM, Lynge E, Bonde J.

Vaccine. 2013 Mar 15;31(12):1604-9. doi: 10.1016/j.vaccine.2012.12.084. Epub 2013 Jan 10.

PMID:
23313651
34.

Immunosuppression and risk of cervical cancer.

Dugué PA, Rebolj M, Garred P, Lynge E.

Expert Rev Anticancer Ther. 2013 Jan;13(1):29-42. doi: 10.1586/era.12.159. Review.

PMID:
23259425
35.

Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study.

Rebolj M, Helmerhorst T, Habbema D, Looman C, Boer R, van Rosmalen J, van Ballegooijen M.

BMJ. 2012 Oct 31;345:e6855. doi: 10.1136/bmj.e6855.

36.

The problem of false-positive human papillomavirus DNA tests in cervical screening.

Rebolj M, Pribac I, Frederiksen ME, Lynge E.

Curr Pharm Des. 2013;19(8):1439-49. Review.

PMID:
23016777
37.

Outcomes in cervical screening using various cytology technologies: what's age got to do with it?

Barken SS, Rebolj M, Lynge E, Junge J, Rygaard C.

Eur J Cancer Prev. 2013 Jul;22(4):367-73. doi: 10.1097/CEJ.0b013e328359cbe0. Erratum in: Eur J Cancer Prev. 2014 Mar;23(2):147.

PMID:
22976387
38.

Non-participation in screening: the case of cervical cancer in Denmark.

Dugué PA, Lynge E, Bjerregaard B, Rebolj M.

Prev Med. 2012 Mar-Apr;54(3-4):266-9. doi: 10.1016/j.ypmed.2012.01.012. Epub 2012 Jan 24.

PMID:
22300964
39.

Introduction of human papillomavirus vaccination in Nordic countries.

Sander BB, Rebolj M, Valentiner-Branth P, Lynge E.

Vaccine. 2012 Feb 14;30(8):1425-33. doi: 10.1016/j.vaccine.2011.11.097. Epub 2011 Dec 7. Review.

PMID:
22154773
40.

Restriction of human papillomavirus DNA testing in primary cervical screening to women above age 30: systematic review.

Rebolj M, Njor SH, Lynge E.

Eur J Cancer Prev. 2012 Jan;21(1):73-81. doi: 10.1097/CEJ.0b013e3283498dbe. Review.

PMID:
21968690
41.

Register-based studies of cancer screening effects.

Von Euler-Chelpin M, Lynge E, Rebolj M.

Scand J Public Health. 2011 Jul;39(7 Suppl):158-64. doi: 10.1177/1403494811401479.

PMID:
21775376
42.

The Danish National Patient Register.

Lynge E, Sandegaard JL, Rebolj M.

Scand J Public Health. 2011 Jul;39(7 Suppl):30-3. doi: 10.1177/1403494811401482.

PMID:
21775347
43.

Human papillomavirus testing and genotyping in cervical screening.

Rebolj M, Lynge E, Bonde J.

Expert Rev Anticancer Ther. 2011 Jul;11(7):1023-31. doi: 10.1586/era.11.84. Review.

PMID:
21806326
44.

Frequency of cervical intraepithelial neoplasia treatment in a well-screened population.

Barken SS, Rebolj M, Andersen ES, Lynge E.

Int J Cancer. 2012 May 15;130(10):2438-44. doi: 10.1002/ijc.26248. Epub 2011 Aug 20.

45.

Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review.

Rebolj M, Bonde J, Njor SH, Lynge E.

BMJ. 2011 May 23;342:d2757. doi: 10.1136/bmj.d2757. Review.

46.
47.

False-positive Human Papillomavirus DNA tests in cervical screening: it is all in a definition.

Rebolj M, Pribac I, Lynge E.

Eur J Cancer. 2011 Jan;47(2):255-61. doi: 10.1016/j.ejca.2010.08.010.

PMID:
20833033
48.

Re: Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

Lynge E, Rebolj M.

J Natl Cancer Inst. 2010 May 19;102(10):739; author reply 739-40. doi: 10.1093/jnci/djq109. Epub 2010 Apr 1. No abstract available.

PMID:
20360534
49.

Has cytology become obsolete as a primary test in screening for cervical cancer?

Rebolj M, Lynge E.

J Med Screen. 2010;17(1):1-2. doi: 10.1258/jms.2009.009098. No abstract available.

PMID:
20356936
50.

Challenges to cervical screening in a developing country: The case of Malaysia.

Othman NH, Rebolj M.

Asian Pac J Cancer Prev. 2009;10(5):747-52.

Supplemental Content

Loading ...
Support Center